Temsirolimus
Top View
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- International Nonproprietary Names for Pharmaceutical Substances (INN)
- CTAC Meeting Minutes, July 10, 2013
- Neratinib Plus Paclitaxel Vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer the Nefert-T Randomized Clinical Trial
- HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
- Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) After Progression on Trastuzumab
- Different Immunological Effects of the Molecular Targeted Agents Sunitinib, Everolimus and Temsirolimus in Patients with Renal Cell Carcinoma
- Endometrial Cancer Molecular Characterization: the Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?
- Torisel (Temsirolimus)
- Mtor Signaling in Cancer and Mtor Inhibitors in Solid Tumor Targeting Therapy
- Torisel® (Temsirolimus)
- A Phase II Study of Everolimus in Patients with Advanced Solid Malignancies with TSC1, TSC2, NF1, NF2 Or STK11 Mutations
- Specialty Injectables Prior Authorization List
- Label [See Warnings and Precautions (5)]
- Clinical Protocol a Phase 1B, Open Label, Dose Finding Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitin
- Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment Yang Liu1-4,*, Srilakshmi Pandeswara2, Vinh Dao1-2, Álvaro Padrón2, Justin M
- Drug Eruptions Associated with Tumor Therapy: Great Imitators
- Oncology Comprehensive Drug List Krogerspecialtypharmacy.Com